Novartis AG is embracing a tough launch environment for cholesterol-lowering PSCK9 inhibitors with the $9.7bn acquisition of The Medicines Co. But Novartis believes the first-in-class small-interfering RNA (siRNA) drug inclisiran that it is acquiring has several advantages over the existing drugs on the market that will make it a blockbuster winner.
Those advantages include a more convenient dosing regimen, which will also translate to a lower cost, and a potentially more...





